Jones Day advises BioPontis Alliance for Rare Diseases
Jones Day partners Cristiana Spontoni and Howard Liebman of the Firm's Brussels Office have been working with BioPontis Alliance in establishing their Brussels-based facility. BioPontis collaborates with patient organizations and academic researchers to identify and vet research their experts believe can be developed into treatments for rare diseases.
BioPontis Alliance recently announced the establishment of its Brussels, Belgium based Public Utility Foundation, providing a nonprofit footprint in the U.S. and in Europe, and allowing the organization to fundraise in Europe. It will provide for tax deductions for philanthropic support in Europe, once BioPontis has registered in the Transnational Giving Platform TGE (applicable in 18 European countries) as well as in the U.S. through its recognition as a 501(c)3 charity.
"As a partner of Jones Day, I have been pleased to provide pro bono advice to the BioPontis Alliance for Rare Diseases, as I am extremely supportive of its mission and its unique approach to developing therapies for rare disease patients," said Ms. Spontoni. "Assisting BioPontis has enabled the Firm to continue its efforts in support of programs of critical social significance. In the case of BioPontis, we were honored to help, in our own small way, the millions of rare disease patients seeking treatment. Senior partner Howard Liebman and I, as well as our team, are excited to have been part of the founding of the Brussels-based BioPontis Public Utility Foundation, and have been inspired by the passion the Board and management of BioPontis brings to this important cause."
For more information, read the BioPontis press release.
Jones Day is a global law firm with 42 offices in major centers of business and finance throughout the world. Its unique governance system fosters an unparalleled level of integration and contributes to its perennial ranking as among the best in the world in client service. Jones Day provides significant legal representation for almost half of the Fortune 500, Fortune Global 500, and FT Global 500.